Replies to post #101111 on NorthWest Biotherapeutics Inc (NWBO)

[Extremist223]

Last time I checked its >32%. I can't find the paper in my bookmarks. Mutations lead to more mutations Dok, there is absolutely no way that drift is = 0. Drift rate could be relative to how many mutations you have, which would meant the mesenchymals would drift faster? Obviously the type of mutation also matters, its been a long time but arent reading frame changes from a loss of a nucleotide the worst, just swapping a nucleotide out would lead to an aberrant protein and rarely hit a promoter.

That isn't to say the drift isn't enough to over come DCVAX SAY WHAT?!!

[sentiment_stocks]

Hi Dok...

I'd like to think that if DCVax-L is proven to make a significant difference in the mesenchymal subgroup that if they can't predetermine who these patients are early enough, that the FDA would then make it available to all GBM patients. With its safety record, it would certainly not harm the patient.

I'm not sure if I've mentioned this to you or not, or if you already came across this... but in this video where LL is answering questions with Dr. Cobb, she states that it is the IDH1 mutation negative wild-type tumor that does well on DCVax-L.

48:10
But some of our data from our immunotherapy trials (note: plural) though, actually have shown immune therapy actually may be more beneficial in the, you know, mesenchymal subgroup of glioblastomas, which actually tend to be IDH1 mutation negative… the IDH1 wild-type tumors. And potentially, these tumors do worse because they have more mutations, and they tend to be more aggressive. That being said, the fact that they have more mutations may actually make them more susceptible to immunotherapy because they have more targets. You know, there are mutations that the immune system can target.